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Unsulfated N”-acetyl-hirudin4s 65 (MDL 27 589), which corresponds to the C-terminus of hlrudin,~65, was 
synthesized by solid-phase methods. The synthetic peptide was able to inhibit fibrin formation and the re- 
lease of fibrinopeptide A from fibrinogen by thrombin. The catalytic site of thrombin was not perturbed 
by the synthetic peptide as H-D-Phe-Pip-Arg-pNA hydrolysis (amidase activity) was not affected. The binding 
of synthetic peptide and thrombin was assessed by isolation of the complex on gel-filtration chromato- 
graphy. A smgle binding site with a binding affinity (K,) of approx. 1.0 x lo5 M-l was observed for 
thrombin-hirudind5 ~65 interaction. The data suggest hat the C-terminal residues 45-65 of hirudin contain 
a binding domain which recognizes thrombin and yet does not bind to the catalytic site of the enzyme. 
Thrombin; Hirudin; Thrombm inhibitor; Fibrinogen clot; (Leech) 
1. INTRODUCTION 
Hirudin is a 65 amino acid peptide isolated from 
the salivary gland of the blood sucking leech 
(Hirudo medicinalis). The complete amino acid se- 
quence of this peptide has been recently reported 
[I,21 and is shown in fig.1. Hirudin is a potent an- 
ticoagulant forming a tight association (Ki = 8 x 
lo-” M) with thrombin and inhibiting the 
cleavage of fibrinogen by thrombin. It has been 
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proposed, based on homology to fibrinopeptides, 
that the C-terminal portion of hirudin may be the 
locus of important binding regions [4]. For exam- 
ple, Tyr-63 is sulfated in the native hirudin 
molecule; loss of this sulfate group results in a 
2-fold loss in potency [4]. Some small C-terminal 
peptides have been synthesized and their an- 
ticoagulant activity assessed [5]. As with hirudin, 
the unsulfated Tyr-63 analogs have one-half the 
potency of the sulfated peptide. W-Acetyl-hirudin 
40-48 amide exhibited no thrombin inhibiting ac- 
tivity [6]. In view of the fact that no small 
oligopeptides have yet been shown to be highly 
specific for thrombin and that the enzyme may 
have an extended or multiple binding region that 
gives it its specificity, the larger C-terminal frag- 
ment unsulfated W-acetyl-hirud&-65 (MDL 
27589) was synthesized. Based on the fibrinopep- 
tide homology, this peptide potentially contains 
the domains in which one binds to the catalytic site 
of thrombin and the other binds to another 
recognition site on the enzyme [4]. 
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2. MATERIALS AND METHODS 
2.1. Peptide synthesis 
The peptide was synthesized by solid-phase 
methods using 0.5 mmol of a 0.66 mmol/g Boc- 
Gln-PAM resin. Double symmetrical anhydride 
couplings were performed with 2.0 mmol N”-Boc- 
amino acid (Peptides International) except in the 
case of Boc-Gln and Boc-Asn which were coupled 
by the DCC/HOBT method. The side chain pro- 
tection utilized was: Asp(Chx), Glu(Bzl), His(Tos), 
Lys(2,ddiClZ), Ser(Bzl), Thr(Bzl), Tyr(2-BrZ). 
Upon completion of the synthesis the N”-Boc pro- 
tection was removed with 50% trifluoroacetic acid 
in methylene chloride. The resin was washed three 
times with methylene chloride, neutralized with 
three washings of 10% diisopropylethylamine in 
methylene chloride, washed three times with 
methylene chloride, acetylated with N-acetylimi- 
dazole in methylene chloride, washed three times 
with methylene chloride, and dried in vacua. The 
peptide was deprotected and cleaved from the resin 
with HF containing 2% anisole at 0°C for 35 min. 
The HF was removed in vacua at O”C, the peptide 
precipitated with ethyl ether, extracted from the 
resin with 30% aqueous acetic acid and 
lyophilized .
2.2. Purification and characterization 
The peptide was desalted on a 92 x 2.6 cm 
Sephadex G-15 column in 5% aqueous acetic acid 
and lyophilized. Preparative HPLC was perform- 
ed on a Cl8 Vydac 218TPlOlO (250 x 10 mm) col- 
umn with 24% acetonitrile in 0.1% aqueous 
trifluoroacetic acid at 5 ml/min. The major peak 
was collected and lyophilized leaving 173 mg of the 
desired product (28% yield based on initial resin 
substitution). Homogeneity was determined by 
HPLC (fig.2) and TLC. HPLC Vydac 218TP54 
(250 x 4.6 mm) Cl8 column, 2 ml/min, to = 
1.9 min: time of elution with a 15-40% 
acetonitrile in 0.1% trifluoroacetic acid linear gra- 
dient at l%/min is 13.3 min; k’ in 21% 
acetonitrile in 0.1% trifluoroacetic acid is 
4.61 min. TLC: (Merck 5715 20 x 20 cm silica gel 
60 plates, 0.25 mm thickness) n-butanol/acetic 
acid/water/pyridine (6: 1.2 : 4.8 : 6) Rf = 0.29; 
isopropanol/conc. ammonium hydroxide/water 
(3: 1: 1) Rf = 0.36; n-butanol/acetic acid/water 
(4:5:5) Rf = 0.84. FAB-MS: (M + H) = 2513.9 f 
1 m.u. (calcd 2514.1). Amino acid analysis: (HCl 
hydrolysis, 24 h, 106°C) 84% peptide content by 
weight, Asx 2.99(3), Thr 0.99(l), Ser 0.81(l), Glx 
5.93(6), Pro 3.02(3), Gly 1.04(l), Ile 0.98(l), Leu 
1.05(l), Tyr 0.96(l), Phe 1.02(l), His 1.01(l), Lys 
1.02(l), NH3 3.01(3). 6280 = 1297. 
2.3. Fibrin clot assay 
Bovine thrombin (Sigma) was titrated to an ap- 
propriate concentration so that fibrin clot forma- 
tion could be monitored by a spectrophotometer 
within 60 min at 405 nm. For the assay, 50,ul of 
thrombin (0.2 pmol) were added to microtiter 
wells (microtiter plate, Falcon) containing 50 ~1 of 
hirudin or synthetic hiruditis-65 (O-25 nmol). The 
solution was agitated by a minimix (Fisher) for 
1 min at 24°C after which time 100~1 of diluted 
human plasma (1 : lo), collected in a final EDTA 
concentration of 0.1070, was added and mixed for 
20 s. The turbidity of the clot was immediately 
monitored by a microplate autoreader (EL309, 
Bio-Tek Instruments) at 405 nm and recorded 
every 3 min. All the reagents used above were 
diluted in an assay buffer containing 0.12 M NaCl, 
0.01 M sodium phosphate, 0.01% NaN3 and 0.1% 
bovine serum albumin (PBS-BSA), pH 7.4. 
2.4. Fibrinopeptide A radioimmunoassay 
The release of fibrinopeptide A from fibrinogen 
in human plasma following the addition of throm- 
bin was determined by a commercially available kit 
purchased from Mallinckrodt Chemical Works. 
Samples in the presence or absence of inhibitors 
were incubated in the microtiter plate and the reac- 
tion condition was identical to that described 
above. After 30 min incubation, a 10 ~1 sample 
from each microtiter well was diluted 1: 200 with 
PBS-BSA buffer containing thrombin inhibitor 
provided in the kit. The diluted sample (200~1) 
was used for fibrinopeptide A determination. The 
sensitivity of the assay for fibrinopeptide A was 
between 2-40 ng/ml with inter- and intra- 
coefficient of variation less than 5%. 
2.5. Amidase activity assay 
The inhibition activity of hirudin and its syn- 
thetic peptide was measured by the ability to in- 
hibit the amidase activity of thrombin from 
releasing p-nitroanilide from H-D-Phe-Pip-Arg- 
pNA (S-2238, Kabi Vitrum, Sweden). The assay 
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conditions were identical to the clotting assay ex- 
cept 100 ~1 of H-D-Phe-Pip-Arg-pNA was used in- 
stead of human plasma. The increase of 
absorbance was monitored at 405 nm and data 
recorded over a 30 min period. 
cording to the method described [7]. A Scatchard 
plot using 1251-hirudin45-65 was analyzed for the 
determination of B/F ratios [8]. 
3. RESULTS 
2.6. Interaction between thrombin and synthetic 3.1. Synthesis, purification and characterization 
hirudinrs-6s 
Highly purified thrombin (kindly provided by 
Dr J.W. Fenton, New York Department of 
Health), showing one single component by HPLC 
and polyacrylamide gel electrophoresis in SDS, 
was used for the binding studies with hirudim5-6s. 
In a typical assay, 1 nmol thrombin was incubated 
with O-16 nmol hirudin45_ss at 24°C for 5 min in 
a final volume of 150~1 of a PBS buffer without 
albumin. Hirudin+65 bound and unbound to 
thrombin were separated by a gel filtration TSK- 
G3OOOSW column (LKB, 8 x 300 mm) at 
0.5 ml/min. Quantitative binding was determined 
by the displacement of 12?-labeled hirudirk+65 
from thrombin with unlabeled hirudimtls-6s. In the 
absence of thrombin, ‘251-labeled peptide co-eluted 
with unlabeled peptide. ‘251-labeled hirudi%-6s 
was prepared by the chloramine-T procedure ac- 
of himdims-65 
[Tyr-63]-N”-Acetyl-hirudin45-65 (fig. 1) was syn- 
thesized in 28% overall yield by standard solid- 
phase peptide synthesis techniques and purified by 
gel filtration and HPLC. The isolated peptide was 
homogeneous by HPLC (fig.2) and TLC and gave 
the expected amino acid analysis and FAB-MS 
(M + H) peak. N- and C-terminal fragmentation in 
the FAB-MS gave some confirmation of the se- 
quence. 
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Fig. 1. Amino acid sequence of hirudin [ 1,2]. Three 
disulfide linkages are at the positions designated as *, ** 
and ***, respectively. Tyrosine at position 63 is sulfated. 
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Fig.2. Purification of synthetic hirudim5_65 on HPLC. 
The profiles of peptide monitoring at 215 nm after HF 
cleavage (A) and after preparative HPLC (B) are shown 
(see section 2). 
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Fig.3. Inhibition of clot activity of thrombin by native 
hirudin and synthetic hirudin45-65. Thrombin (0.2 pmol) 
was incubated with the inhibitors at 24°C for 5 min in 
a microtiter plate (see section 2). Turbidity was recorded 
over a 170 min time period following the addition of 
human plasma. 
3.2. Inhibition of fibrin clot formation 
The synthetic peptide was initially tested for its 
ability to inhibit the clotting activity of thrombin. 
Human plasma was used as a source of fibrinogen 
for the clot assay. Fibrin clot formation was as- 
sessed by the increase of turbidity after the addi- 
tion of thrombin. Kinetic analysis of the effect of 
peptide 45-65 on clot formation is shown in fig.3. 
The maximal turbidity in the absence of inhibitors 
was reached within a 60 min time period. Both 
hirudin and the synthetic fragment completely in- 
hibited the clotting activity of thrombin. To 
achieve 50% inhibition (ICSO) at 30 min incuba- 
tion, IO4 times as much synthetic hirudin45_6s was 
required as compared to native hirudin. 
3.3. Inhibition of the release of fibrinopeptide A
Fibrinopeptide A is a major cleavage product 
following the hydrolysis of fibrinogen by throm- 
bin. The inhibition of fibrinopeptide A formation 
by hirudin and the synthetic peptide was in- 
vestigated. The synthetic peptide inhibited the 
fibrinopeptide A release. However, it required a 
lo4 times greater dose than hirudin for 50% inhibi- 
tion at 30 min (fig.4). The kinetics of the clot for- 
mation and fibrinopeptide A release is different. 
The release of fibrinopeptide A was complete in 
5 min (not shown) with 0.2 pmol thrombin. This 
was much faster than the time required for max- 
imal clot formation monitored by turbidity change 
(fig.3). 
3.4. Inhibition of amidase activity of thrombin 
It has been suggested that for fibrinogen another 
recognition site on thrombin exists which is distinct 
from its catalytic site (responsible for amidase ac- 
tivity) [3]. The recognition binding site may ac- 
count for the high specificity of thrombin toward 
certain protein substrates. H-D-Phe-Pip-Arg-pNA 
was used as a substrate for testing the amidase ac- 
tivity of thrombin. This substrate has a moderate 
affinity for thrombin (Km = 10e5 M) and can serve 
as a sensitive probe of the catalytic site. Fig.5 
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Fig.4. Inhibition of the thrombin-mediated release of 
fibrinopeptide A by native hirudin and synthetic 
hirudin.+65. Experimental conditions were identical to 
those described in fig.3. The reaction was terminated 
after 30 min and the amount of fibrinopeptide A (FPA) 
released was determined by a radioimmunoassay. 
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shows that synthetic peptide 45-65 did not inhibit 
the amidase activity of thrombin at concentrations 
where clot formation was inhibited. The data in- 
dicate that the C-terminal 45-65 region does not 
block the catalytic site of thrombin, but only binds 
to a secondary binding region of thrombin and 
thereby inhibits the fibrinopeptide A release from 
fibrinogen and subsequent clotting. 
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Fig.5. Inhibition of thrombin amidase activity by native 
hirudin and synthetic hirudims-65. Thrombin activity 
was determined with Phe-Pip-Arg-pNA as substrate. 
The experimental conditions were identical to that 
described in fig.3, except that lOOpi of synthetic 
substrate was used instead of plasma. The enzyme 
reaction was monitored for 30 min. 
3.5. Direct binding between thrombin and 
synthetic hirudinrs-65 
To provide direct evidence that hirudin45_65 
binds to thrombin, the complex was isolated and 
characterized by a gel-filtration HPLC technique. 
12?-labeled peptide was used to quantitate the in- 
teraction. A typical profile for the binding of 
thrombin and synthetic hirudinzs-6s is depicted in 
fig.6. Equilibrium was reached within 1 min as 
evidenced by no further change of the radioactivity 
distribution after 4 h. The stoichiometry between 
thrombin and hirudims-65 was 1: 1 as demonstrat- 
ed by the saturation curve (fig.7). Scatchard plot 
analysis indicates that there is only a single binding 
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Fig.6. Formation of thrombin-hirudin complex. 1251-labeled hirud&-65 was incubated with thrombin (1 nmol) at 24°C 
in a final volume of 150 al. Thrombin-hiruditis-65 binding was determined by HPLC on a TSK-3000SW column. (A) 
Molecular mass markers and rZ51-hirudin45-~~. (B) 12’I-hirudin45-,s~ (1 ng, lo4 cpm) thrombin (1 nmol). (C) “‘I- 
hirudin+65 was displaced from the thrombin in the presence of 4 nmol unlabeled hirudin45_65. The mixture was 
allowed to react for 1 h prior to HPLC separation. The first peak represents the complex of thrombin-hirudin.,5-65, 
while the second peak represents the unassociated hirudir&-65. (D) Same as panel C, but the reaction was allowed to 
proceed for 4 h prior to HPLC separation. 
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Fig.7. Scatchard plot of thrombin-hirudk-6s 
interaction. Bound and free rz51-hirudim5-a5 were 
determined by HPLC (fig.6). 1 nmol thrombin was 
bound saturably by 1 nmol hirudin+65 in the presence 
of hirudims-65 at doses greater than 4 nmol (inset). 
site on thrombin for hirudirt4_6s with a binding af- 
finity (&) about 1 x lo5 M-’ (fig.7). 
4. DISCUSSION 
Thirty years ago, the blood clotting inhibitor 
from medicinal leeches, hirudin, was isolated and 
characterized [9] as a single polypeptide with 
specific antithrombin activity. Some of the phar- 
macodynamic and pharmacokinetic properties of 
hirudin and its influence on various forms of 
thrombosis in animals have been recently in- 
vestigated [lo]. A quantitative immunoassay for 
hirudin has also been developed [111. However, the 
mode of thrombin-hirudin interaction and func- 
tional site(s) of hirudin have not been well 
established. The tight binding (& - lo-” M) and 
almost irreversible inhibition of thrombin by 
hirudin had led to the speculation that the 
thrombin-hirudin interaction must comprise multi- 
ple binding sites [12]. A study with carboxypep- 
tidase Y suggested that the last 7 amino acids 
(residues 59-65) are essential for the hirudin- 
thrombin interaction [4]. It was also proposed that 
the reactive sites (including the protein binding and 
catalytic sites) of hirudin to thrombin might be 
located outside the disulfide-bridged loops (fig. 1) 
of hirudin, namely, residues 47-65 [4]. However, 
this hypothesis has never been tested ex- 
perimentally. 
In the present study, we show that residues 
45-65 inhibit the clotting activity and the release 
of fibrinopeptide A by thrombin. The synthetic 
peptide 45-65 binds to thrombin and occupies a 
single binding site on thrombin (fig.7). The 
binding affinity (Ka) is about 10’ M-l, a value only 
one order of magnitude less than the thrombin- 
fibrinogen interaction (Ka - 10’ M-l). Since the 
synthetic peptide does not inhibit the hydrolysis of 
H-D-Phe-Pip-Arg-pNA by thrombin, we suggest 
that the C-terminal region of hirudin may not be 
directly involved in the catalytic binding site of 
thrombin. A similar finding was reported in a re- 
cent study with thrombomodulin (Mr 84000), 
isolated from endothelial membrane [ 131. 
Jakubowski et al. [13] showed that the protein 
binds to thrombin and inhibits clotting activity and 
yet does not inhibit the catalytic activity of 
thrombin. 
The importance of the N-terminal portion of 
hirudin (residues l-44) which contains 3 disulfide 
loops is not known. It is possible that a catalytic 
binding domain is located within these 3 loops, 
similar to the other proteinase inhibitor proteins: 
aprolinium, pancreatic secretory trypsin inhibitor, 
potato inhibitor I, and potato inhibitor II. All the 
binding domains in these inhibitors are present in 
the disulfide loops. Oxidation of the disulfide 
bridges of hirudin by performic acid drastically af- 
fects the biological activity of native hirudin to 
thrombin [14]. The N-terminal region may also 
mediate the amidase inhibition of thrombin by 
steric hindrance. Experiments are in progress to 
synthesize longer peptides in order to determine 
the possible role of the N-terminus of the hirudin 
molecule. 
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